Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 77,80€(+256,88%). Der Median liegt bei 75,20€(+244,95%).
Kaufen | 8 |
Halten | 11 |
Verkaufen | 3 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months. Paul Stoffels1, MD, CEO and Chair of the Board of Directors of Galapagos, said “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad will remain with the company until August 1, 2025 to ensure a smooth handover of responsibilities. We thank Thad for his contributions and wish him the best as he pursues other opportunities.”» Mehr auf globenewswire.com
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.» Mehr auf globenewswire.com
Galapagos to Present at Upcoming Investor Conferences
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March: TD Cowen 45 th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: Here Barclays 27 th Annual Global Healthcare Conference Date: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: Here A live webcast of the presentations can also be accessed on the Investors page of the Company's website at www.glpg.com/investors. Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days. About Galapagos We are a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For additional information, please visit www.glpg.com or follow us on LinkedIn or X. For further information, please contact:» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 75,50 Mio | 136,10% |
Bruttoeinkommen | −37,43 Mio | 87,25% |
Nettoeinkommen | 25,31 Mio | 83,94% |
EBITDA | −53,87 Mio | 17,15% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 1,46 Mrd€ |
Anzahl Aktien | 66,56 Mio |
52 Wochen-Hoch/Tief | 27,33€ - 19,57€ |
Dividenden | Nein |
Beta | -0,01 |
KGV (PE Ratio) | 26,05 |
KGWV (PEG Ratio) | 0,03 |
KBV (PB Ratio) | 0,67 |
KUV (PS Ratio) | 5,27 |
Unternehmensprofil
Galapagos NV, ein integriertes biopharmazeutisches Unternehmen, beschäftigt sich mit der Entdeckung, Entwicklung und Vermarktung verschiedener Medikamente für einen hohen ungedeckten medizinischen Bedarf. Zu seinen Pipeline-Produkten gehört Filgotinib, ein JAK1-Inhibitor, der sich in verschiedenen Phasen der klinischen Erprobung für die Behandlung von rheumatoider Arthritis, Morbus Crohn, Colitis ulcerosa, Dünndarm-CD, fistelnder CD, ankylosierender Spondylitis, Psoriasis-Arthritis und Uveitis befindet. Die Pipeline-Produkte des Unternehmens umfassen auch GLPG1972, das eine Phase-2b-Studie zur Behandlung von Osteoarthritis abgeschlossen hat, Toledo-Moleküle, darunter GLPG3970, GLPG4399 und GLPG4876 zur Behandlung von Entzündungen, sowie GLPG4716 und Ziritaxestat zur Behandlung von idiopathischer Lungenfibrose. Zu den weiteren Produkten in der Pipeline gehören GLPG2737, ein Transmembran-Leitfähigkeitsregulator für zystische Fibrose, der sich in klinischen Phase-2-Studien zur Behandlung von Patienten mit autosomal-dominanter polyzystischer Nierenerkrankung befindet, und GLPG0555, ein JAK1-Inhibitor, der sich in Phase 1b zur Behandlung von Patienten mit Osteoarthritis befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Gilead Sciences, Inc., AbbVie S.à r.l. und Novartis Pharma AG. Galapagos NV wurde 1999 gegründet und hat seinen Hauptsitz in Mechelen, Belgien.
Name | GALAPAGOS N.V. ADR 1 |
CEO | Dr. Paulus A. Stoffels M.D., Ph.D. |
Sitz | Mechelen, Belgien |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 704 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | GLPG |
Frankfurt | GXEA.F |
Düsseldorf | GXEA.DU |
Assets entdecken
Shareholder von GALAPAGOS N.V. ADR 1 investieren auch in folgende Assets